-
Tumor Necrosis Factor Inhibitor Drugs Industry Analysis Report 2025: Key Trends, Drivers, and Forecast Insights
24 Nov 2025 00:00 GMT
… FDA approvals, a rise in disease incidence, clinical research and trials … drugs are utilized in the treatment … Pharmaceuticals, a company based in the US, collaborated with a biotechnology … arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, …
-
RINVOQ® Demonstrated Superiority Versus HUMIRA® for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor
20 Oct 2025 16:43 GMT
… in Phase 3 clinical trials for alopecia areata, … of prescription drugs to the FDA. Visit www.fda.gov… any vaccines
Also tell your doctor about all the medicines you … Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken …
-
Lupin Gets Expert Committee Nod To Conduct Phase I Trial of Certolizumab Pegol, IGRA TB Test Made Mandatory
01 Sep 2025 13:23 GMT
… ), under the Central Drugs Standard Control Organisation … with US Licensed Cimzia (certolizumab pegol) … disease, rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, … Single-Period, Two-Treatment, Parallel, Comparative Pharmacokinetics …
-
Alvotech & Advanz Pharma ink European supply and commercialization agreement for biosimilar candidate to Cimzia
02 Jul 2025 03:51 GMT
… biotech company specializing in the development and manufacture of biosimilar medicines … UK headquartered global pharmaceutical company with a … s biosimilar candidate to Cimzia (certolizumab pegol).
“Our … market share as treatment for chronic rheumatic …
-
Alvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia® (certolizumab pegol)
01 Jul 2025 08:00 GMT
… Alvotech’s biosimilar candidate to Cimzia® (certolizumab pegol). “Our … significant market share as treatment for chronic rheumatic diseases … Alvotech
Alvotech is a biotech company, founded by … disease medicines. Advanz Pharma is a global pharmaceutical company …
-
Uveitis Treatment Market Size to Reach USD 4.69 Billion by 2032, Driven by Advancements in Biologics and Rising Prevalence of Autoimmune Disorders – SNS Insider
19 Jun 2025 13:51 GMT
… corticosteroids and other medications are often more … presence of key pharmaceutical and biotechnology companies. High R … the U.S. FDA provides regulatory support for … Trial Trends and Drug Development Pipeline
6. Competitive Landscape
7. Uveitis Treatment …
-
How to opt for potentially more affordable medications when treating some autoimmune or autoinflammatory diseases
05 Jun 2025 16:18 GMT
… with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing … vaccines.
Also tell your doctor about all the medicines … US by AbbVie Biotechnology Ltd; Organon … Biologics: More Treatment Choices. US Food and Drug Administration; …
-
Alvotech Completes Acquisition Of Xbrane R&D Organization And Biosimilar Candidate To Cimzia
06 Jun 2025 16:14 GMT
… biotech company specializing in the development and manufacture of biosimilar medicines … Sweden and biosimilar candidate to Cimzia (certolizumab pegol). All regulatory … Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), …
-
Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug
05 Jun 2025 18:20 GMT
… U.S. Food and Drug Administration (FDA) approved Teva and Alvotech Selarsdi … , XB003, which is based on Cimzia (certolizumab pegol) for around SEK275 …
-
Record-breaking FDA biosimilar approvals to create opportunities for drug developers, manufacturers, GlobalData finds
20 May 2025 15:44 GMT
… products like UCB SA’s Cimzia and Johnson & Johnson … in clinical supply chains, major pharmaceutical companies' intentions to … the type of drug and timeframe for trial start-up—as … and specialized requirements for trials and manufacturing due to …
About
© 1995-2025